替比培南匹伏酯对细菌感染小鼠败血症的体内抗菌作用  

In vivo activity of tebipenem pivoxil in septicemia mouse infected by bacteria

作　　者：钟巍[1] 李耘[1] 吕媛[1] 李曼宁[1] 曲春明[1] 

机构地区：[1]北京大学第一医院临床药理研究所,北京100191

出　　处：《中国新药与临床杂志》2014年第11期839-841,共3页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的评价替比培南匹伏酯对我国近年临床分离细菌感染小鼠的体内抗菌作用。方法选取临床分离的金黄色葡萄球菌、肺炎链球菌、大肠埃希菌和流感嗜血杆菌各1株。以0．5mL最低致死菌量感染小鼠分别建立小鼠败血症实验模型，分别以按1：0．7间距设置的不同浓度替比培南匹伏酯、法罗培南0．5mL灌胃给药，记录给药后1～7d内小鼠成活率，用BLISS法计算ED_50、ED_95及P值。结果对4株临床分离致病菌的体内保护试验显示，替比培南对金黄色葡萄球菌、肺炎链球菌、大肠埃希菌和流感嗜血杆菌均有很好的体内抗菌保护作用，ED50值在0．535～5．262mg·kg^-1，均明显优于对照药法罗培南（P〈0．01）。结论国产替比培南匹伏酯对我国临床分离致病菌具有广谱的、较强的体内抗菌作用，值得进一步研究。AIM To evaluate the in vivo activity of tebipenem pivoxil in the experimental therapy of mouse septicemia caused by clinical isolated pathogenic bacteria in recent years in China. METHODS A total of 4 strains were involved in the study： Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli and Haemophilus influenzae. The mice were intraperitoneally injected with 0.5 mL of minimum lethal dose （MLD） bacteria and experimental model of mouse septicemia was established. Tebipenem pivoxil and faropenem were each intragastric administered 0.5 mL in a single dose with different concentrations according to the rate of 1 ： 0.7. The survival of the infected mice were monitored for 7 days, and the 50% and 95% effective dose （ED_50, ED_95） was determined by the BLISS method. RESULTS The ED_50 of tebipenem pivoxil against Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzaev were 0.535 - 5.262 mg·kg^-1, much better than those of faropenem （P 〈 0.01）. CONCLUSLON Domestic tebipenem pivoxil showed a good in vivo activity for gram-positive and negative bacterial.

关 键 词：替比培南 出血性败血症 小鼠 体内研究 

分 类 号：R978.1[医药卫生—药品]